FDA Approves First Generic Strattera For ADHD Treatment

The Federal Food and Drug Administration (FDA) has approved the first generic version of Strattera, an atomoxetine used in the treatment of attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult consumers. The generic drug will be manufactured in multiple strengths by Apotex Inc., Aurobindo Pharma Limited, Glenmark Pharmaceuticals Limited, and Teva Pharmaceuticals USA, Inc.

This was reported by The U.S. Food and Drug Administration on May 30, 2017.

Contact Information: U.S. Food and Drug Administration Center for Drug Evaluation and Research, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993; 888-463-6332; Email: druginfo@fda.hhs.gov . . .